Developer docs
API playgroundTry for free, no card

Search company profiles

Oncocross

Full company profile

uuid0003n7q

Namestring
Oncocross
Legal namestring
ONCOCROSS CO., LTD.
Websiteurl
oncocross.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Oncocross Co., Ltd. is a South Korea-based, KOSDAQ-listed (ticker 449740, listed December 2024) AI-driven precision medicine company operating across drug discovery, diagnostics, and data assetization. The company was founded in June 2015 and built around a multi-omics AI platform that integrates transcriptomics, proteomics, metabolomics, and spatial proteomics data to support pharmaceutical and medical research partners. Its product portfolio consists of four interrelated layers: Neo Omics, an LC/MS-based multi-omics analysis service with end-to-end automation; the Digital Bio-Bank (DBB), a data assetization platform linking clinical (RWD), omics, and pathology data across 10,000+ clinical/genomic records and 2,700+ biospecimens; ONCOfind AI, a blood-based liquid-biopsy platform for cancer-of-unknown-primary prediction, early cancer detection, and post-treatment monitoring; and RAPTOR AI v2.0, the next-generation indication-discovery and mechanism-interpretation engine that also supports new modalities such as ADCs, bispecific antibodies, and targeted protein degraders. The company also operates an internal drug pipeline (OC212e for anti-cancer, OC901 for neurodegenerative disorders) and partnered/optioned assets (OC514 licensed to Korea Pharma for sarcopenia after completing Phase I; DW1023 jointly developed with Daewoong Pharmaceutical).

Short descriptiontext

Oncocross is a South Korea-based, KOSDAQ-listed AI precision medicine company using multi-omics analytics platforms — RAPTOR AI and ONCOfind AI — to enable pharmaceutical and research partners in drug discovery, indication expansion, biomarker development, and early cancer detection.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, multi-omics analysis, precision medicine platform, biomarker discovery services, digital biobanking
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Laboratory Analytical Instruments3826
Product category
AI-Driven Drug Discovery & Precision Medicine
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Project-based Services (Neo Omics)
TypeOthers
Description

Multi-omics analysis services for cell, tissue, and liquid specimens provided on a project basis. Starting point for service revenue.

oncocross.com
2Joint Research & Development
TypeProfessional Services
Description

Collaborative drug discovery partnerships with pharmaceutical companies for indication expansion, target discovery, and biomarker development. Revenue from research collaboration fees and potential milestone payments.

oncocross.com
3Licensing & Technology Transfer
TypeLicensing Royalties
Description

License-out of proprietary drug candidates (e.g., OC514 to Korea Pharma) and technology transfer agreements.

oncocross.com
4Data Services & Analytics
TypeData Monetisation
Description

DBB-based data analytics, biomarker discovery, and precision medicine data services leveraging integrated clinical and multi-omics datasets.

oncocross.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing
ModelProfessional services/ project-basedBilling cadenceProject-based
Notes

Neo Omics services customized according to project objectives, sample types, and analysis scope. Pricing varies by project scope and complexity.

oncocross.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1OncoMaster
Description

Clinical and genomic data platform acquired and integrated by Oncocross, serving as the foundation for Digital Bio-Bank (DBB) and precision medicine data business.

oncocross.com
Core offering1 text field

Oncocross develops and operates AI-driven precision medicine platforms that combine multi-omics data (transcriptomics, proteomics, metabolomics, spatial proteomics) with proprietary AI models to support pharmaceutical drug discovery, cancer diagnostics, and data assetization. Its commercial offerings include the RAPTOR AI® and ONCOfind AI® platforms, a fee-for-service multi-omics laboratory business (Neo Omics), and a Digital Bio-Bank (DBB) data assetization platform, sold through direct enterprise engagement with pharmaceutical companies and research institutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 150+ scientific publications in peer-reviewed journals demonstrating platform capabilities
+2 more records
Product overview1 text field

Oncocross operates as a platform-based AI-driven precision medicine company with four integrated core products: Neo Omics (LC/MS-based multi-omics analysis service), DBB (Digital Bio-Banking for clinical-omics-pathology data assetization), ONCOfind AI® (multi-omics-based early cancer detection, primary site prediction, and post-treatment monitoring), and RAPTOR AI® VERSION 2.0 (AI platform for indication discovery, mechanism interpretation, and new modality development). The company also develops proprietary drug pipelines (OC212e — anti-cancer, OC901 — neurodegenerative disorders, OC514 — sarcopenia completed Phase I) and partnered pipelines (DW1023 with Daewoong). The portfolio spans from multi-omics data generation through data assetization to AI-powered diagnostics and drug discovery.

Product and service3 records
1RAPTOR AI® Version 2.0
CategoryAI Drug Discovery Platform
Description

Next-generation AI platform that supports candidate indication discovery, mechanism-of-action interpretation, and new modality development (ADCs, bispecific antibodies, TPD) based on Asian multi-omics data and automated experimental infrastructure. Sold to pharmaceutical and biotech partners for drug discovery R&D.

2ONCOfind AI®
CategoryAI Diagnostics Platform
Description

AI-powered multi-omics analytics platform integrating blood-based genomic, transcriptomic, proteomic, and metabolomic data for cancer primary site prediction, early cancer detection, and post-treatment monitoring. Targets diagnostic and clinical applications.

3Neo Omics
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership48 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Absorption merger decision (April 2026) with merger ratio of 1:5.2100960. OncoMaster's clinical and genomic data assets integrated with Oncocross's AI platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Vascular tissue-based AI biomarker joint research.

3Omics AI
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-01
Description

Strategic investment of KRW 2 billion in Omics AI, combining the investment with OmicsAI's automation system to promote popularization of high-cost protein analysis services through automation.

mt.co.kr
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Joint business agreement on AI-based digital biobanking.

5UNIST
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Joint research team identified new metabolomic biomarkers for precision liver cancer diagnosis.

oncocross.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

AI-driven future medicine research collaboration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

AI future medicine research collaboration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

National project on AI-based next-generation ADC therapeutics development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Rare disease drug development collaboration with Canadian university and foundation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Rare disease drug development project with Canadian university.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

AI-based joint drug development research collaboration with Canadian AI company Variational AI.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

AI-based joint drug development research collaboration.

13Seoul National University Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Next-generation AI drug development research collaboration with Seoul National University Hospital.

oncocross.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Drug development collaboration with Canadian AI company.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-01
Description

AI-based joint drug development collaboration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Partnership for AI-powered drug discovery development.

17Seoul National University Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Joint AI drug development research collaboration.

oncocross.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

AI drug development research collaboration with Canadian company.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Research collaboration with Canadian AI company for drug development.

20Seoul National University Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Joint research for next-generation AI drug development.

oncocross.com
21Korea University Medical Center / KCMC Holdings
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-01
Description

K-Bio technology commercialization model with 148 licensing agreements and $55.3M contract value; M&A outcome including oncoMASTER merger into Oncocross.

thebionews.net
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-01
Description

Drug evaluation service on peptide asset.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

Drug evaluation service for indication expansion of 3 drugs under development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-03-01
Description

Indication expansion collaboration for KANARB (hypertension treatment) using AI-driven drug repurposing.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-01
Description

Liver disease treatment drug joint research and development collaboration with Swiss biotech AlphaMol.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-01
Description

MOU for collaborative research and medical AI development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-06-01
Description

Partnership for therapeutic development in oncology and myelofibrosis treatment using Cyclica's AI-powered drug discovery platform combined with Oncocross's multi-omics capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Anti-cancer drug research collaboration using Oncocross's AI platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Rare disease drug research collaboration with French biotech 4P Pharma.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

AI-based clinical research collaboration.

Strategic tierMinorTypeOthersAnnounced on2021-10-01
Description

Selected for GO AUSTRIA program organized by Austrian government (2021).

32Cytogen
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-01
Description

Research collaboration agreement.

oncocross.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-07-01
Description

AI-powered obesity treatment drug development using inhalation fat research.

34UC Berkeley SkyDeck
Strategic tierMinorTypeOthersAnnounced on2021-05-01
Description

Selected for SkyDeck accelerator program at UC Berkeley (2021).

oncocross.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

Strategic investment and joint research collaboration for drug indication expansion. Daewoong invested in Oncocross while collaborating on AI-driven drug development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

Research collaboration agreement for AI drug discovery.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

Research collaboration with prestigious US academic medical center.

38HLB
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

Anti-cancer drug development MOU.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

MOU for collaborative research.

40Choong Nam University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

AI drug discovery research collaboration MOU.

oncocross.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

Joint research collaboration agreement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

Anti-cancer drug development MOU.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-01
Description

Medical AI research collaboration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-01
Description

COVID-19 & Dengue Fever research collaboration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-08-01
Description

Material Transfer Agreement (MTA) for cancer research.

46Seoul National University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-01
Description

MOU on PharmDB-K research collaboration.

oncocross.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-01
Description

Clinical Development Agreement (CDA) on sarcopenia treatment.

48Korea Research Institute of Chemical Technology
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-10-01
Description

MOU for collaborative research.

oncocross.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery platform combining multi-omics data with automated wet-lab experimentation to develop small-molecule therapeutics - directly overlapping Oncocross's RAPTOR AI drug discovery model and target/biomarker discovery use cases.

TypeDirect peer
Description

Machine learning platform that integrates multi-omics data, phenotypic screening, and disease modeling for drug discovery - directly comparable to Oncocross's RAPTOR AI approach of combining multi-omics and AI for indication discovery.

TypeDirect peer
Description

AI-driven precision medicine company using patient-derived multi-omics data for drug discovery and indication expansion - directly aligned with Oncocross's indication discovery and partnered pharma collaboration model.

TypeBroad incumbent
Description

Physics-based computational platform for molecular simulation and drug discovery with broader materials science footprint - competes in same AI drug discovery category as Oncocross but operates as established software-plus-collaborations incumbent.

TypeDirect peer
Description

Korean AI drug discovery company applying machine learning to identify novel therapeutic targets and drug candidates - direct domestic peer with same Korean pharma customer base and overlapping indication-expansion capabilities.

TypeDirect peer
Description

AI-augmented drug discovery platform with multi-omics integration for polypharmacology and target discovery - directly comparable to Oncocross's RAPTOR AI, and notably already a strategic partner (2022 joint research agreement).

TypeDirect peer
Description

AI platform combining biomedical knowledge graphs with multi-omics data for target identification and drug discovery - similar AI-for-pharma model with comparable partnership-driven revenue structure.

TypeDirect peer
Description

Korean AI-driven drug discovery company focused on novel target identification using deep learning over multi-omics data - direct domestic peer competing for same Korean pharma partnerships and pipeline assets.

TypeDirect peer
Description

Liquid biopsy and multi-omics-based cancer diagnostics company with blood-based early detection and monitoring capabilities - directly comparable to Oncocross's ONCOfind AI diagnostic platform for cancer detection and treatment monitoring.

TypeBroad incumbent
Description

Asia-headquartered genomics and multi-omics services provider with large-scale sequencing, proteomics, and bioinformatics - comparable as broader incumbent in multi-omics data generation and Asian precision medicine data assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oncocross

AI-Driven Drug Discovery & Precision Medicineoncocross.com

Oncocross is a South Korea-based, KOSDAQ-listed AI precision medicine company using multi-omics analytics platforms — RAPTOR AI and ONCOfind AI — to enable pharmaceutical and research partners in drug discovery, indication expansion, biomarker development, and early cancer detection.

What Oncocross does

Oncocross Co., Ltd. is a South Korea-based, KOSDAQ-listed (ticker 449740, listed December 2024) AI-driven precision medicine company operating across drug discovery, diagnostics, and data assetization. The company was founded in June 2015 and built around a multi-omics AI platform that integrates transcriptomics, proteomics, metabolomics, and spatial proteomics data to support pharmaceutical and medical research partners. Its product portfolio consists of four interrelated layers: Neo Omics, an LC/MS-based multi-omics analysis service with end-to-end automation; the Digital Bio-Bank (DBB), a data assetization platform linking clinical (RWD), omics, and pathology data across 10,000+ clinical/genomic records and 2,700+ biospecimens; ONCOfind AI, a blood-based liquid-biopsy platform for cancer-of-unknown-primary prediction, early cancer detection, and post-treatment monitoring; and RAPTOR AI v2.0, the next-generation indication-discovery and mechanism-interpretation engine that also supports new modalities such as ADCs, bispecific antibodies, and targeted protein degraders. The company also operates an internal drug pipeline (OC212e for anti-cancer, OC901 for neurodegenerative disorders) and partnered/optioned assets (OC514 licensed to Korea Pharma for sarcopenia after completing Phase I; DW1023 jointly developed with Daewoong Pharmaceutical).

Oncocross firmographics

Firmographics
Name
Oncocross
Legal name
ONCOCROSS CO., LTD.
Website
https://oncocross.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Oncocross is a South Korea-based, KOSDAQ-listed AI precision medicine company using multi-omics analytics platforms — RAPTOR AI and ONCOfind AI — to enable pharmaceutical and research partners in drug discovery, indication expansion, biomarker development, and early cancer detection.
Ownership category
akta.pro rank

Oncocross industry classification

Industry
Product category
AI-Driven Drug Discovery & Precision Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Multi-omics analysis
  • Precision medicine platform
  • Biomarker discovery services
  • Digital biobanking

Where Oncocross is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Oncocross business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Project-based Services (Neo Omics): Multi-omics analysis services for cell, tissue, and liquid specimens provided on a project basis. Starting point for service revenue.
  2. Joint Research & Development: Collaborative drug discovery partnerships with pharmaceutical companies for indication expansion, target discovery, and biomarker development. Revenue from research collaboration fees and potential milestone payments.
  3. Licensing & Technology Transfer: License-out of proprietary drug candidates (e.g., OC514 to Korea Pharma) and technology transfer agreements.
  4. Data Services & Analytics: DBB-based data analytics, biomarker discovery, and precision medicine data services leveraging integrated clinical and multi-omics datasets.

Pricing tiers

ModelBillingPrice
Professional services/ project-basedProject-basedCustom project-based pricing

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Oncocross product offering

Product offering

Core offering

Oncocross develops and operates AI-driven precision medicine platforms that combine multi-omics data (transcriptomics, proteomics, metabolomics, spatial proteomics) with proprietary AI models to support pharmaceutical drug discovery, cancer diagnostics, and data assetization. Its commercial offerings include the RAPTOR AI® and ONCOfind AI® platforms, a fee-for-service multi-omics laboratory business (Neo Omics), and a Digital Bio-Bank (DBB) data assetization platform, sold through direct enterprise engagement with pharmaceutical companies and research institutions.

Product overview

Oncocross operates as a platform-based AI-driven precision medicine company with four integrated core products: Neo Omics (LC/MS-based multi-omics analysis service), DBB (Digital Bio-Banking for clinical-omics-pathology data assetization), ONCOfind AI® (multi-omics-based early cancer detection, primary site prediction, and post-treatment monitoring), and RAPTOR AI® VERSION 2.0 (AI platform for indication discovery, mechanism interpretation, and new modality development). The company also develops proprietary drug pipelines (OC212e — anti-cancer, OC901 — neurodegenerative disorders, OC514 — sarcopenia completed Phase I) and partnered pipelines (DW1023 with Daewoong). The portfolio spans from multi-omics data generation through data assetization to AI-powered diagnostics and drug discovery.

Differentiator

Problem solved

Functional benefit

Brands

  • OncoMaster: Clinical and genomic data platform acquired and integrated by Oncocross, serving as the foundation for Digital Bio-Bank (DBB) and precision medicine data business.

Products and services

  • RAPTOR AI® Version 2.0 Next-generation AI platform that supports candidate indication discovery, mechanism-of-action interpretation, and new modality development (ADCs, bispecific antibodies, TPD) based on Asian multi-omics data and automated experimental infrastructure. Sold to pharmaceutical and biotech partners for drug discovery R&D.
  • ONCOfind AI® AI-powered multi-omics analytics platform integrating blood-based genomic, transcriptomic, proteomic, and metabolomic data for cancer primary site prediction, early cancer detection, and post-treatment monitoring. Targets diagnostic and clinical applications.
  • Neo Omics

Quantifiable outcome

  • 150+ scientific publications in peer-reviewed journals demonstrating platform capabilities
  • +2 more outcomes

Companies that use Oncocross

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Oncocross technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Oncocross partnerships and signals

Strategic signal

Partnerships

48 partnerships are on record, tiered core and minor.

  • OncoMastercoreStrategic or Co-development Partner · 1 May 2026Absorption merger decision (April 2026) with merger ratio of 1:5.2100960. OncoMaster's clinical and genomic data assets integrated with Oncocross's AI platform.
  • Human & BiocoreStrategic or Co-development Partner · 1 May 2026Vascular tissue-based AI biomarker joint research.
  • Omics AIcoreTechnology or Integration · 1 January 2026Strategic investment of KRW 2 billion in Omics AI, combining the investment with OmicsAI's automation system to promote popularization of high-cost protein analysis services through automation.
  • Chung-Ang University HospitalcoreStrategic or Co-development Partner · 1 December 2025Joint business agreement on AI-based digital biobanking.
  • UNISTcoreStrategic or Co-development Partner · 1 October 2025Joint research team identified new metabolomic biomarkers for precision liver cancer diagnosis.
  • Chonnam National University Hwasun HospitalcoreStrategic or Co-development Partner · 1 October 2025AI-driven future medicine research collaboration.
  • Chonnam National University Hwasun HospitalcoreStrategic or Co-development Partner · 1 October 2025AI future medicine research collaboration.
  • AptiscoreStrategic or Co-development Partner · 1 October 2025National project on AI-based next-generation ADC therapeutics development.
  • Université Laval / ARSACS FoundationcoreStrategic or Co-development Partner · 1 September 2025Rare disease drug development collaboration with Canadian university and foundation.
  • Université Laval / ARSACS FoundationcoreStrategic or Co-development Partner · 1 September 2025Rare disease drug development project with Canadian university.
  • Variational AI Inc.coreStrategic or Co-development Partner · 1 July 2025AI-based joint drug development research collaboration with Canadian AI company Variational AI.
  • Variational AI Inc.coreStrategic or Co-development Partner · 1 July 2025AI-based joint drug development research collaboration.
  • Seoul National University HospitalcoreStrategic or Co-development Partner · 1 June 2025Next-generation AI drug development research collaboration with Seoul National University Hospital.
  • Variational AI Inc.coreStrategic or Co-development Partner · 1 June 2025Drug development collaboration with Canadian AI company.
  • Variational AI Inc.coreTechnology or Integration · 1 June 2025AI-based joint drug development collaboration.
  • Variational AI Inc.coreStrategic or Co-development Partner · 1 June 2025Partnership for AI-powered drug discovery development.
  • Seoul National University HospitalcoreStrategic or Co-development Partner · 1 June 2025Joint AI drug development research collaboration.
  • Variational AI Inc.coreStrategic or Co-development Partner · 1 June 2025AI drug development research collaboration with Canadian company.
  • Variational AI Inc.coreStrategic or Co-development Partner · 1 June 2025Research collaboration with Canadian AI company for drug development.
  • Seoul National University HospitalcoreStrategic or Co-development Partner · 1 June 2025Joint research for next-generation AI drug development.
  • Korea University Medical Center / KCMC HoldingscoreStrategic or Co-development Partner · 1 May 2025K-Bio technology commercialization model with 148 licensing agreements and $55.3M contract value; M&A outcome including oncoMASTER merger into Oncocross.
  • Kine SciencecoreStrategic or Co-development Partner · 1 July 2024Drug evaluation service on peptide asset.
  • JW PharmaceuticalcoreStrategic or Co-development Partner · 1 April 2024Drug evaluation service for indication expansion of 3 drugs under development.
  • BoryungcoreStrategic or Co-development Partner · 1 March 2023Indication expansion collaboration for KANARB (hypertension treatment) using AI-driven drug repurposing.
  • AlphaMol SciencecoreStrategic or Co-development Partner · 1 November 2022Liver disease treatment drug joint research and development collaboration with Swiss biotech AlphaMol.
  • Gachon University Gil Medical CentercoreStrategic or Co-development Partner · 1 September 2022MOU for collaborative research and medical AI development.
  • Cyclica Inc.coreStrategic or Co-development Partner · 1 June 2022Partnership for therapeutic development in oncology and myelofibrosis treatment using Cyclica's AI-powered drug discovery platform combined with Oncocross's multi-omics capabilities.
  • Donghwa PharmaceuticalcoreStrategic or Co-development Partner · 1 January 2022Anti-cancer drug research collaboration using Oncocross's AI platform.
  • 4P Pharma (Institut Pasteur de Lille)coreStrategic or Co-development Partner · 1 November 2021Rare disease drug research collaboration with French biotech 4P Pharma.
  • Korea University Anam HospitalcoreStrategic or Co-development Partner · 1 November 2021AI-based clinical research collaboration.
  • Austria Wirtschaftsservice (AWS)minorOthers · 1 October 2021Selected for GO AUSTRIA program organized by Austrian government (2021).
  • CytogencoreStrategic or Co-development Partner · 1 July 2021Research collaboration agreement.
  • 365mccoreStrategic or Co-development Partner · 1 July 2021AI-powered obesity treatment drug development using inhalation fat research.
  • UC Berkeley SkyDeckminorOthers · 1 May 2021Selected for SkyDeck accelerator program at UC Berkeley (2021).
  • Daewoong PharmaceuticalcoreStrategic or Co-development Partner · 1 April 2021Strategic investment and joint research collaboration for drug indication expansion. Daewoong invested in Oncocross while collaborating on AI-driven drug development.
  • Samsung Medical CentercoreStrategic or Co-development Partner · 1 April 2021Research collaboration agreement for AI drug discovery.
  • Columbia University Medical CentercoreStrategic or Co-development Partner · 1 April 2021Research collaboration with prestigious US academic medical center.
  • HLBcoreStrategic or Co-development Partner · 1 April 2021Anti-cancer drug development MOU.
  • CHA Bundang Medical CentercoreStrategic or Co-development Partner · 1 April 2021MOU for collaborative research.
  • Choong Nam UniversitycoreStrategic or Co-development Partner · 1 April 2021AI drug discovery research collaboration MOU.
  • Cyclica Inc.coreStrategic or Co-development Partner · 1 April 2021Joint research collaboration agreement.
  • HLR Life SciencescoreStrategic or Co-development Partner · 1 April 2021Anti-cancer drug development MOU.
  • Bundang CHA HospitalcoreStrategic or Co-development Partner · 1 April 2021Medical AI research collaboration.
  • ST PharmcoreStrategic or Co-development Partner · 1 September 2020COVID-19 & Dengue Fever research collaboration.
  • Cancer Research UKcoreStrategic or Co-development Partner · 1 August 2020Material Transfer Agreement (MTA) for cancer research.
  • Seoul National UniversitycoreStrategic or Co-development Partner · 1 February 2020MOU on PharmDB-K research collaboration.
  • MD Anderson Cancer CentercoreStrategic or Co-development Partner · 1 February 2020Clinical Development Agreement (CDA) on sarcopenia treatment.
  • Korea Research Institute of Chemical TechnologycoreStrategic or Co-development Partner · 1 October 2018MOU for collaborative research.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Oncocross competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining multi-omics data with automated wet-lab experimentation to develop small-molecule therapeutics - directly overlapping Oncocross's RAPTOR AI drug discovery model and target/biomarker discovery use cases.
  • Insitro: Machine learning platform that integrates multi-omics data, phenotypic screening, and disease modeling for drug discovery - directly comparable to Oncocross's RAPTOR AI approach of combining multi-omics and AI for indication discovery.
  • Exscientia: AI-driven precision medicine company using patient-derived multi-omics data for drug discovery and indication expansion - directly aligned with Oncocross's indication discovery and partnered pharma collaboration model.
  • Standigm: Korean AI drug discovery company applying machine learning to identify novel therapeutic targets and drug candidates - direct domestic peer with same Korean pharma customer base and overlapping indication-expansion capabilities.
  • Cyclica: AI-augmented drug discovery platform with multi-omics integration for polypharmacology and target discovery - directly comparable to Oncocross's RAPTOR AI, and notably already a strategic partner (2022 joint research agreement).
  • Benevolent AI: AI platform combining biomedical knowledge graphs with multi-omics data for target identification and drug discovery - similar AI-for-pharma model with comparable partnership-driven revenue structure.
  • Deargen: Korean AI-driven drug discovery company focused on novel target identification using deep learning over multi-omics data - direct domestic peer competing for same Korean pharma partnerships and pipeline assets.
  • Guardant Health: Liquid biopsy and multi-omics-based cancer diagnostics company with blood-based early detection and monitoring capabilities - directly comparable to Oncocross's ONCOfind AI diagnostic platform for cancer detection and treatment monitoring.

Broad incumbents

  • Schrödinger: Physics-based computational platform for molecular simulation and drug discovery with broader materials science footprint - competes in same AI drug discovery category as Oncocross but operates as established software-plus-collaborations incumbent.
  • BGI Genomics: Asia-headquartered genomics and multi-omics services provider with large-scale sequencing, proteomics, and bioinformatics - comparable as broader incumbent in multi-omics data generation and Asian precision medicine data assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Oncocross social profiles

Digital presence

Oncocross financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oncocross leadership team

Management profile

Number of profiles

Profiles7 records

Oncocross subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Oncocross funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oncocross M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncocross

What does Oncocross do?

Oncocross develops and operates AI-driven precision medicine platforms that combine multi-omics data (transcriptomics, proteomics, metabolomics, spatial proteomics) with proprietary AI models to support pharmaceutical drug discovery, cancer diagnostics, and data assetization. Its commercial offerings include the RAPTOR AI® and ONCOfind AI® platforms, a fee-for-service multi-omics laboratory business (Neo Omics), and a Digital Bio-Bank (DBB) data assetization platform, sold through direct enterprise engagement with pharmaceutical companies and research institutions.

Is Oncocross a public or private company?

Oncocross is a public company. It is classified as public and is currently operating.

When was Oncocross founded?

Oncocross was founded in 2015. It employs 11 to 50 people.

Where is Oncocross based?

Oncocross is headquartered in Seoul, South Korea, in the Asia region.

How does Oncocross make money?

Four revenue lines are on record. Project-based Services (Neo Omics) is the primary driver. The others are joint Research & Development, licensing & Technology Transfer and data Services & Analytics.

Who are Oncocross's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Exscientia, Standigm, Cyclica, Benevolent AI, Deargen and Guardant Health. Broad incumbents are Schrödinger and BGI Genomics.

Does Oncocross have an API?

No public API is recorded for Oncocross.

What industry is Oncocross in?

Oncocross's product category is AI-Driven Drug Discovery & Precision Medicine. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Life Science Company NewsThe Rise of K-BiotechSouth Korea is positioning itself to become a global biotech and pharmaceutical innovation hub by 2030, backed by a $19 billion R&D budget and a target to grow its biotechnology output nearly fivefold to $149 billion by 2035. The country's biopharma market, currently valued at $22 billion, has produced over 1,300 new drug candidates in the past three years, representing 10% of the global total and surpassing R&D leaders like the UK, Switzerland, and Japan. International pharmaceutical companies including GSK, Merck, AstraZeneca, and Daiichi Sankyo are investing in Korea through licensing deals and manufacturing facilities, while Korean biotech firms such as Orum Therapeutics, Alteogen, and Oncocross are raising capital and forming partnerships to advance oncology and AI-driven drug development pipelines.Business Wire BlogOncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using AI in Anticancer and Regenerative MedicineOncocross and JW Pharmaceutical signed a joint research agreement to develop new anticancer and regenerative medicine drugs using Oncocross's AI platform RAPTOR. The collaboration aims to identify new indications for JW's first-in-class pipeline, building on a 2022 agreement that secured positive data on an orphan disease indication.Business Wire BlogOncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using AI in Anticancer and Regenerative MedicineOncocross and JW Pharmaceutical signed a joint research agreement to develop new anticancer and regenerative medicine drugs using Oncocross's AI platform RAPTOR. The collaboration aims to identify new indications for JW's first-in-class pipeline, building on a 2022 agreement that secured positive data on an orphan disease indication.YahooOncocross Expands Collaboration with JW Pharmaceutical on Developing Innovative New Drugs Using AI in Anticancer and Regenerative MedicineOncocross and JW Pharmaceutical signed a joint research agreement on May 22, 2024, to develop new drugs using Oncocross's AI platform RAPTOR AITM. The collaboration aims to identify new indications for JW Pharmaceutical's first-in-class anticancer and regenerative medicine pipelines, building on a 2022 agreement that yielded positive orphan disease data.Oncocross온코크로스 : we make drugs worksThe provided text is a corporate history timeline for OncoCros rather than a news article reporting a specific current event. It lists various past milestones including investments, partnerships, and clinical trials conducted by the company and its partners between 2015 and 2026. Because there is no single core event to analyze for sentiment or immediate impact, the content is treated as non-narrative data.https://www.avcj.comKorean AI drug developer secures $14m Series BOncocross, a South Korean AI drug developer, raised KRW16.5 billion ($14 million) in Series B funding led by Smilegate and GNTech. The company is in talks with strategic investors for a KRW10-20 billion pre-IPO round, expected in the second half of next year. It has 16 pipeline candidates, with five set to begin clinical trials within 12 months.